nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.07.2012 | Preclinical Study

Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells

verfasst von: Keiko Kajitani, Yuka Tanaka, Koji Arihiro, Tsuyoshi Kataoka, Hideki Ohdan

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

We investigated the role of human natural killer (NK) cells in the peripheral blood (PB) and liver in controlling breast cancer. The proportion of NK cells among liver mononuclear cells was significantly higher than among PB mononuclear cells. Liver NK cells inductively expressed higher levels of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) than PB NK cells in response to interleukin-2 (IL-2). Liver NK cells displayed higher cytotoxicity against various breast cancer cell lines (MDA-MB231, MDA-MB453, MDA-MB468, and MCF-7) after IL-2 stimulation than did PB NK cells. Anti-HER2 monoclonal antibody (mAb) promoted the cytotoxicity of both the types of NK cells toward HER2-expressing cell lines. All breast cancer cell lines highly expressed death-inducing TRAIL receptors, death receptor 4, but did not express death-inhibitory receptors (DcR1 and DcR2). Both PB and liver NK cell-induced cytotoxicity was inhibited partially by anti-TRAIL mAb and more profoundly by the combination of anti-TRAIL mAb and concanamycin A, indicating that TRAIL and perforin are involved. IL-2-stimulated liver and PB NK cells exhibited upregulated expression of CXCR3, which bind to the chemokines CXCL9, CXCL10, and CXCL11 secreted by breast cancer cells. We also found that IFN-γ promoted the production of CXCL10 from breast cancer cells. The results of this study show that IFN-γ secreted from NK cells likely promotes the production of CXCL10 from breast cancer cells, which in turn accelerates the migration of CXCR3-expressing NK cells into the tumor site. These findings suggest the possibility of a therapeutic approach by either activation of endogenous PB and liver NK cells or adoptive transfer of in vitro-activated autologous NK cells.

Nur mit Berechtigung zugänglich

Trinchieri G (1989) Biology of natural killer cells. Adv Immunol 47:187–376PubMedCrossRef

Robertson MJ, Ritz J (1990) Biology and clinical relevance of human natural killer cells. Blood 76(12):2421–2438PubMed

Cullen SP, Martin SJ (2008) Mechanisms of granule-dependent killing. Cell Death Differ 15(2):251–262PubMedCrossRef

Pardo J, Aguilo JI, Anel A, Martin P, Joeckel L, Borner C et al (2009) The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation. Microbes Infect 11(4):452–459PubMedCrossRef

Sjostrom-Mattson J, Von Boguslawski K, Bengtsson NO, Mjaaland I, Salmenkivi K, Blomqvist C (2009) The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer. Acta Oncol 48(8):1137–1143PubMedCrossRef

Lahiry L, Saha B, Chakraborty J, Adhikary A, Hossain DM et al (2010) Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells. Carcinogenesis 31(2):259–268PubMedCrossRef

Takahashi M, Ogasawara K, Takeda K, Hashimoto W, Sakihara H, Kumagai K et al (1996) LPS induces NK1.1+ alpha beta T cells with potent cytotoxicity in the liver of mice via production of IL-12 from Kupffer cells. J Immunol 156(7):2436–2442PubMed

Crispe IN, Mehal WZ (1996) Strange brew: T cells in the liver. Immunol Today 17(11):522–525PubMedCrossRef

Seki S, Habu Y, Kawamura T, Takeda K, Dobashi H, Ohkawa T et al (2000) The liver as a crucial organ in the first line of host defense: the roles of Kupffer cells, natural killer (NK) cells and NK1.1 Ag+ T cells in T helper 1 immune responses. Immunol Rev 174:35–46PubMedCrossRef

10.

Ishiyama K, Ohdan H, Mitsuta H, Arihiro K, Asahara T (2006) Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 43(2):362–372PubMedCrossRef

11.

Ochi M, Ohdan H, Mitsuta H, Onoe T, Tokita D, Hara H et al (2004) Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology 39(5):1321–1331PubMedCrossRef

12.

Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS et al (2009) TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 113(2):217–230PubMedCrossRef

13.

Dastjerdi K, Tabar GH, Dehghani H, Haghparast A (2011) Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by cell SELEX. Biotechnol Appl Biochem 58(4):226–230PubMedCrossRef

14.

Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S et al (1996) Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 156(10):3678–3686PubMed

15.

Kawarabayashi N, Seki S, Hatsuse K, Ohkawa T, Koike Y, Aihara T et al (2000) Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 32(5):962–969PubMedCrossRef

16.

Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al (1997) The receptor for the cytotoxic ligand TRAIL. Science 276(5309):111–113PubMedCrossRef

17.

Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D et al (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277(5327):818–821PubMedCrossRef

18.

Wallin RP, Screpanti V, Michaelsson J, Grandien A, Ljunggren HG (2003) Regulation of perforin-independent NK cell-mediated cytotoxicity. Eur J Immunol 33(10):2727–2735PubMedCrossRef

19.

Salazar-Mather TP, Orange JS, Biron CA (1998) Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J Exp Med 187(1):1–14PubMedCrossRef

20.

Guimond MJ, Wang B, Croy BA (1998) Engraftment of bone marrow from severe combined immunodeficient (SCID) mice reverses the reproductive deficits in natural killer cell-deficient tg epsilon 26 mice. J Exp Med 187(2):217–223PubMedCrossRef

21.

Hedrick JA, Saylor V, Figueroa D, Mizoue L, Xu Y, Menon S et al (1997) Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J Immunol 158(4):1533–1540PubMed

22.

Groom JR, Luster AD (2011) CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89(2):207–215PubMedCrossRef

23.

Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J (1990) Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 171(5):1509–1526PubMedCrossRef

24.

Nagler A, Lanier LL, Phillips JH (1990) Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J Exp Med 171(5):1527–1533PubMedCrossRef

25.

Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C et al (1993) Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 91(1):123–132PubMedCrossRef

26.

Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW, Ritz J (1992) Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol 22(1):1–6PubMedCrossRef

27.

Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319(6055):675–678PubMedCrossRef

28.

Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3(6):673–682PubMedCrossRef

29.

Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y et al (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364(6440):806–809PubMedCrossRef

30.

Nagata S (1997) Apoptosis by death factor. Cell 88(3):355–365PubMedCrossRef

31.

Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104(2):155–162PubMedCrossRef

32.

Walczak H, Miller RE, Ariail K, Gliniak B, Griffith T, Kubin M et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5(2):157–163PubMedCrossRef

33.

Herr I, Debatin KM (2001) Cellular stress response and apoptosis in cancer therapy. Blood 98(9):2603–2614PubMedCrossRef

34.

Nagler A, Lanier LL, Cwirla S, Phillips JH (1989) Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 143(10):3183–3191PubMed

35.

Ishigami S, Natsugome S, Tokuda K, Nakajo A, Xiangming Che, Iwashige H et al (2000) Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88(3):577–583PubMedCrossRef

36.

Villegas FR, Santiago C, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J et al (2002) Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35(1):23–28PubMedCrossRef

37.

Hyakudomi M, Matsubara T, Hyakudomi R, Yamamoto T, Kinugasa S, Yamanoi A et al (2008) Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol 15(6):1775–1782PubMedCrossRef

38.

Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8):3051–3057PubMedCrossRef

39.

Klingemann HG, Martinson J (2004) Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy 6(1):15–22PubMedCrossRef

40.

Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316(15):889–897PubMedCrossRef

41.

Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M et al (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178(4):1223–1230PubMedCrossRef

42.

Takeda K, Hayakawa Y, Smyth ML, Kayagaki N, Yamaguchi N, Kakuta S et al (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 1:94–100CrossRef

43.

Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M et al (2000) Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191(5):771–780PubMedCrossRef

44.

Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N et al (2001) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med 193(6):661–670PubMedCrossRef

45.

Talmadge JE, Phillips H, Schindler J, Tribble H, Pennigton R (1987) Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res 47(21):5725–5732PubMed

46.

Helms MW, Prescher JA, Cao YA, Schaffert S, Contag CH (2010) IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol Immunother 59(9):1325–1334PubMedCrossRef

47.

Pegram HJ, Haynes NM, Smyth MJ, Kershaw MH, Darcy PK (2010) Characterizing the anti-tumor function of adoptively transferred NK cells in vivo. Cancer Immunol Immunother 59(8):1235–1246PubMedCrossRef

48.

Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN et al (2010) A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 59(12):1781–1789PubMedCrossRef

49.

Milani V, Stangl S, Issels R, Gehrmann M, Wagner B, Hube K (2009) Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy—a case report. J Transl Med 7:50PubMedCrossRef

50.

Knorr DA, Kaufman DS (2010) Pluripotent stem cell-derived natural killer cells for cancer therapy. Transl Res 156(3):147–154PubMedCrossRef

Titel: Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells
verfasst von: Keiko Kajitani
Yuka Tanaka
Koji Arihiro
Tsuyoshi Kataoka
Hideki Ohdan
Publikationsdatum: 01.07.2012
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1944-x

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines

Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy

Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation

Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer

Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie